Core Insights - Intuitive announced a $45 million donation to the Intuitive Foundation, raising total contributions to over $170 million since its establishment in 2018 [1][3][8] Group 1: Foundation's Mission and Contributions - The Intuitive Foundation aims to reduce global disease burden through philanthropy, research, and education, committing over $65 million to various causes since its inception [3][8] - In 2024, the Foundation matched employee donations, contributing over $7 million to more than 2,000 causes [4][5] - Key programs include the Global Surgical Training Challenge, FIRST Robotics sponsorship, and the Surgical Education Learners Forum, which focuses on developing training modules for clinicians in low-resource settings [5][8] Group 2: Leadership Statements - Intuitive CEO Gary Guthart expressed support for the Foundation's work in providing health and medical fellowships and grants globally [2] - Intuitive Foundation President Catherine Mohr highlighted the importance of amplifying employee voices in philanthropic efforts [5]

MedRobot 近日 直观医疗I ntui tive （纳斯达克股票代码： ISRG )频繁被分析师提及——收购经销商、关税问 题的影响等等。 尽管面临供应链挑战， 直观医疗Intuitive（纳斯达克股票代码： ISRG )的新一代手术机器人系统达芬奇5在 2024年取得了显著的成绩。根据公司年度财报数据显示，自2024年3月推出以来，全球共安装了362台达芬奇5 系统，其中174台在第四季度完成安装。全年共有超过2500名外科医生使用该系统完成了32000多例手术，充分 体现了机器人辅助手术的强劲需求。 装机量破万！收入612亿！达芬奇最新财报！ 直观医疗 首席执行官Gary Guthart近日在电话会议上透露了更多信息： # 回顾2024年 全面推出达芬奇5（2024年是针对部分老客户限量销售）；（MedRobot备注：这似乎是在说，既 然关税导致成本压力大，那就努力卖价格更高的达芬奇5） 达芬奇5：价格上涨30%，更多细节见内 ； 最新！达芬奇5数据应用方向大揭秘 顶级设计！直击达芬奇5代机器人新亮点 在美国、德国、保加利亚增加工厂； 开展直销、 增强培训等 等。 收购经销商！达芬奇撸起袖子自己干 ...

Market Cap and Growth Potential - Companies with market caps below $1 trillion but with plausible chances of reaching that milestone could deliver excellent returns to long-term investors [1] - Intuitive Surgical currently has a market cap of $215 billion and would need a compound annual growth rate of 10 8% to reach $1 trillion by 2040 [2] Industry Leadership and Technology - Robotic-assisted surgeries offer benefits such as less bleeding, less scarring, faster recoveries, and shorter hospital stays compared to traditional open surgeries [3] - Intuitive Surgical's da Vinci system is the market leader in robotic-assisted surgical equipment with a 57% market share and an installed base of 9,539 systems as of Q3 2024, a 15% year-over-year increase [4] Growth Opportunities - Less than 5% of eligible surgeries were performed robotically as of early 2023, but this percentage could reasonably rise to 20%, representing a quadrupling of the business even if the total number of surgeries remains static [6] - The aging global population further supports long-term growth potential for robotic-assisted surgeries [6] Competitive Advantages - Intuitive Surgical has a first-mover advantage, having already developed and gained regulatory clearance for its devices, unlike competitors such as Johnson & Johnson and Medtronic [8] - High switching costs for hospitals due to significant investments in da Vinci systems and staff training create a strong moat for the company [9] - The company is an innovator, making strides in artificial intelligence and continuously improving its da Vinci system, which helps maintain its leadership position [10] Historical Performance and Future Outlook - Intuitive Surgical's compound annual growth rate over the past 25 years has been more than double what it needs to achieve to become a trillion-dollar stock by 2040 [12] - The company possesses qualities such as a strong moat, strong growth avenues, and industry leadership, making it an excellent long-term investment in the healthcare sector [12]

Core Insights - Intuitive Surgical's stock experienced a decline despite a strong fourth-quarter earnings report, attributed to its high valuation and slightly below-estimate guidance for 2025 [1][5] Financial Performance - The company reported a 25% increase in overall revenue, reaching $2.41 billion, surpassing the consensus estimate of $2.24 billion [3] - Adjusted earnings per share rose from $1.60 to $2.21, exceeding expectations of $1.79 [4] - Da Vinci procedures increased by 18%, with 493 surgical systems sold, up from 415 a year ago, bringing the installed base to 9,902, a 15% increase [3][4] Growth Drivers - Growth was balanced between instruments and accessories and surgical systems, with the new Ion Endoluminal System experiencing a 70% increase in procedure volume [4] Guidance and Market Reaction - The 2025 guidance indicated a slowdown in growth, projecting procedure growth of 13% to 16%, below Wall Street's consensus of 16% and the 17% growth seen in 2024 [5] - The stock's decline was influenced by concerns over narrowing margins and increased operating expenses, despite the potential for conservative guidance [6] Valuation Considerations - Intuitive Surgical's price-to-earnings ratio is around 80, indicating a premium valuation, which may challenge growth in the short term but suggests long-term potential [6]

Core Viewpoint - Intuitive Surgical reported strong fourth-quarter 2024 results, with adjusted earnings per share (EPS) of $2.21, exceeding estimates and showing significant year-over-year growth [1][10]. Revenue Details - The company achieved revenues of $2.41 billion, reflecting a 24.9% increase year over year and aligning with consensus estimates [2]. - Revenue growth was driven by an increase in installed systems and a rise in da Vinci procedure volume [11]. Segmental Details - **Instruments & Accessories**: Revenues reached $1.41 billion, up 23.7% year over year, supported by an 18% increase in da Vinci procedure volume and significant growth in Ion and SP procedures [3]. - **Systems**: This segment generated $655 million in revenue, a 36.5% year-over-year increase, attributed to higher average selling prices and a decrease in leased systems [4]. - **Services**: Revenues amounted to $347.4 million, marking a 14.1% increase from the previous year [5]. Margins - Adjusted gross profit was $1.68 billion, up 28% year over year, with a gross margin of 69.5%, an increase of approximately 150 basis points [6]. - Adjusted operating income totaled $927.7 million, reflecting a 49.4% year-over-year increase, with an operating margin of 38.4%, up approximately 620 basis points [7]. Financial Position - At the end of the fourth quarter, the company had cash, cash equivalents, and investments totaling $8.83 billion, down from $9.31 billion in the previous quarter [8]. - Total assets increased to $18.74 billion from $17.74 billion a year ago [8]. Market Performance - Despite strong quarterly results, the stock declined by 2.2% in after-hours trading, likely due to prior anticipation of results [10]. - Over the past six months, Intuitive Surgical's shares have risen by 31.5%, outperforming the industry growth of 3.9% and the S&P 500 Index's 12.7% increase [14]. Future Outlook - The company plans to open new manufacturing facilities for da Vinci 5 and Ion systems in 2025, which is expected to enhance future growth [12]. - However, a slowdown in bariatric procedures and a gradual decline in revenues per procedure for Instruments & Accessories are anticipated due to the rise of GLP-1 medications [13].

Financial Data and Key Metrics - No specific financial data or key metrics changes mentioned in the provided content [1][2][3] Business Line Data and Key Metrics - No specific business line data or key metrics changes mentioned in the provided content [1][2][3] Market Data and Key Metrics - No specific market data or key metrics changes mentioned in the provided content [1][2][3] Company Strategy and Industry Competition - No specific company strategy or industry competition details mentioned in the provided content [1][2][3] Management Commentary on Operating Environment and Future Outlook - No specific management commentary on the operating environment or future outlook mentioned in the provided content [1][2][3] Other Important Information - Dan Connolly will be joining Intuitive as VP and Head of Investor Relations in early February, bringing 18 years of experience from a global investment manager and active following of surgical robotics since 2008 [2] - Comments on the call may contain forward-looking statements, and actual results may differ materially from those expressed or implied [3] Q&A Session - No Q&A session details provided in the content [1][2][3]

Financial Performance - Revenue for the quarter ended December 2024 was $2.41 billion, a 25.2% year-over-year increase [1] - EPS for the quarter was $2.21, compared to $1.60 a year ago, representing a 38.1% increase [1] - Revenue matched the Zacks Consensus Estimate of $2.41 billion, with a surprise of -0.02% [1] - EPS exceeded the consensus estimate of $1.77 by 24.86% [1] Stock Performance - Shares of Intuitive Surgical returned +13.7% over the past month, outperforming the Zacks S&P 500 composite's +2.7% change [3] - The stock currently has a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market [3] Key Metrics - Da Vinci Surgical System Installed Base: 9,902, slightly below the 9,912 average estimate [4] - Total System Units Placed - Total Company: 493, exceeding the 434 average estimate [4] - Total System Units Placed - United States: 284, surpassing the 208 average estimate [4] - Total System Units Placed - Outside of the United States: 209, slightly above the 207 average estimate [4] Revenue Breakdown - Revenue- Product (Instruments and accessories and Systems): $2.07 billion, a 27.2% year-over-year increase, exceeding the $1.85 billion estimate [4] - Revenue- Services: $347.40 million, a 14.1% year-over-year increase, slightly above the $345.32 million estimate [4] - Revenue- Systems: $654.60 million, a 36.3% year-over-year increase, surpassing the $504.39 million estimate [4] - Revenue- Instruments and accessories: $1.41 billion, a 23.4% year-over-year increase, exceeding the $1.35 billion estimate [4]

Earnings Performance - Intuitive Surgical reported quarterly earnings of $2 21 per share, beating the Zacks Consensus Estimate of $1 77 per share, representing a 24 86% earnings surprise [1] - The company's earnings per share (EPS) increased from $1 60 per share a year ago, with adjustments for non-recurring items [1] - Over the last four quarters, the company has surpassed consensus EPS estimates four times [2] Revenue Performance - Intuitive Surgical posted revenues of $2 41 billion for the quarter ended December 2024, missing the Zacks Consensus Estimate by 0 02% [2] - Year-over-year revenues increased from $1 93 billion, and the company has topped consensus revenue estimates three times over the last four quarters [2] Stock Performance and Market Comparison - Intuitive Surgical shares have gained approximately 17% since the beginning of the year, outperforming the S&P 500's gain of 3 5% [3] - The stock's immediate price movement sustainability will depend on management's commentary during the earnings call [3] Earnings Outlook and Estimate Revisions - The current consensus EPS estimate for the coming quarter is $1 78 on $2 2 billion in revenues, and $7 87 on $9 55 billion in revenues for the current fiscal year [7] - The estimate revisions trend for Intuitive Surgical is mixed, translating into a Zacks Rank 3 (Hold), indicating expected market-aligned performance [6] Industry Context - Intuitive Surgical belongs to the Zacks Medical - Instruments industry, which is currently in the top 26% of the 250 plus Zacks industries [8] - The top 50% of Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1 [8] Peer Comparison - Glaukos, another company in the Medical - Instruments industry, is expected to post a quarterly loss of $0 43 per share, representing a year-over-year improvement of 31 8% [9] - Glaukos' revenues are expected to be $100 75 million, up 22 3% from the year-ago quarter [9]

Earnings Performance - Intuitive Surgical reported Q4 revenue of $2 41 billion, a 25% YoY increase, surpassing analyst consensus [1] - Q4 earnings were $686 million, or $1 88 per share, up from $606 million, or $1 69 per share, a year ago, beating expectations [1] Procedure and System Growth - Procedures performed with da Vinci surgical devices increased 18% YoY [2] - The company installed 493 da Vinci systems in Q4, compared to 415 a year ago [2] Future Outlook - The company expects da Vinci procedures to grow 13% to 16% in 2024 [3] - Adjusted gross profit margin is expected to decline by 1 to 2 percentage points, excluding potential new tariffs which could have a material impact [3] Stock Performance - Intuitive Surgical shares fluctuated slightly in extended trading after the earnings release [4] - The stock closed at an all-time high the previous day and has gained approximately 62% over the past year [4]

Intuitive Surgical (ISRG) stock skidded late Thursday despite beating profit expectations following a strong sales preannouncement that sent shares on a five-day sprint. During the December quarter, the robotic surgery giant earned an adjusted $2.21 per share, easily beat forecasts for $1.79 a share, according to FactSet. The rest of Intuitive Surgical's report lined up with the preannouncement on Jan. 15 that sent Intuitive Surgical stock flying 7.7%.But in after-hours trades on today's stock market, share ...